Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152

Benzinga · 2d ago
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $137 to $152.